Objective: Arterial allografts are routinely employed for reconstruction of infected prosthetic grafts. Usually, banked cryopreserved arteries are used; however, existing conventional freezing cryopreservation techniques applied to arteries are expensive. In contrast, a new ice-free cryopreservation technique results in processing, storage and shipping methods that are technically simpler and potentially less costly. The objective of this study was to determine whether or not ice-free cryopreservation causes tissue changes that might preclude clinical use. Methods: Conventionally frozen cryopreserved porcine arteries were compared with ice-free cryopreserved arteries and untreated fresh controls using morphological (light, scanning electron and laser scanning microscopy), viability (alamarBlue assay) and hemocompatibility methods (blood cell adhesion, thrombin/antithrombin-III-complex, polymorphonuclear neutrophil-elastase, β-thromboglobulin and terminal complement complex SC5b-9). Results: No statistically significant structural or hemocompatibility differences between ice-free cryopreserved and frozen tissues were detectable. There were no quantitative differences observed for either autofluorescence (elastin) or second harmonic generation (collagen) measured by laser scanning microscopy. Cell viability in ice-free cryopreserved arteries was significantly reduced compared to fresh and frozen tissues (p < 0.05). Conclusions: The formation of ice in aortic artery preservation did not make a difference in histology, structure or thrombogenicity, but significantly increased viability compared with a preservation method that precludes ice formation. Reduced cell viability should not reduce in vivo performance. Therefore, ice-free cryopreservation is a potentially safe and cost-effective technique for the cryopreservation of blood vessel allografts.

Keywords:
Viability, Structural integrity, Cryopreservation, Artery allograft, Hemocompatibility
1.
Adam, M., J.F. Hu, P. Lange, L. Wolfinbarger Jr (1990) The effect of liquid nitrogen submersion on cryopreserved human heart valves. Cryobiology 27: 605–614.
2.
Armiger, L.C. (1998) Postimplantation leaflet cellularity of valve allografts: are donor cells beneficial or detrimental? Ann Thorac Surg 66(suppl 6): 233–235.
3.
Bisdas, T., M. Bredt, M. Pichlmaier, T. Aper, M. Wilhelmi, S. Bisdas, A. Haverich, O.E. Teebken (2010) Eight-year experience with cryopreserved arterial homografts for the in situ reconstruction of abdominal aortic infections. J Vasc Surg 52: 323–330.
4.
Bodnar, E., O. Matsuki, R. Parker, D.N. Ross (1989) Viable and nonviable aortic homografts in the subcoronary position: a comparative study. Ann Thorac Surg 47: 799–805;(discussion)804–805.
5.
Brockbank, K.G.M., A.E. Heacox, K. Schenke-Layland (2010) Guidance for removal of fetal bovine serum from cryopreserved heart valve processing. Cells Tissues Organs 193: 264–273.
6.
Brockbank, K.G.M., F.G. Lightfoot, Y.C. Song, M.J. Taylor (2000) Interstitial ice formation in cryopreserved homografts: a possible cause of tissue deterioration and calcification in vivo. J Heart Valve Dis 9: 200–206.
7.
Brockbank, K.G.M., K. Schenke-Layland, E.D. Greene, Z. Chen, O. Fritze, M. Schleicher, R. Kaulitz, I. Riemann, F. Fend, J.M. Albes, U.A. Stock, M. Lisy (2012) Ice-free cryopreservation of heart valve allografts: better extracellular matrix preservation in vivo and preclinical results. Cell Tissue Bank, E-pub ahead of print.
8.
Brockbank, K.G.M., Y.C. Song (2003) Mechanisms of bioprosthetic heart valve calcification. Transplantation 75: 1133–1135.
9.
Brown, J.W., M. Ruzmetov, O. Eltayeb, M.D. Rodefeld, M.W. Turrentine (2011) Performance of SynerGraft decellularized pulmonary homograft in patients undergoing a Ross procedure. Ann Thorac Surg 91: 416–422;(discussion)422–423.
10.
Burch, P.T., A.K. Kaza, L.M. Lambert, R. Holubkov, R.E. Shaddy, J.A. Hawkins (2010) Clinical performance of decellularized cryopreserved valved allografts compared with standard allografts in the right ventricular outflow tract. Ann Thorac Surg 90: 1301–1305;(discussion)1306.
11.
Campbell, L.H., K.G.M. Brockbank (2010) Cryopreservation of porcine aortic heart valve leaflet-derived myofibroblasts. Bioproc Biobank 8: 211–217.
12.
Clarke, D.R. (1994) Invited letter concerning: accelerated degeneration of aortic allografts in infants and young children. J Thorac Cardiovasc Surg 107: 1162–1164.
13.
Dahl, S.L.M., A. P. Kypson, J. H. Lawson, J. L. Blum, J. T. Strader, Y. Li, R. J. Manson, W E. Tente, L. DiBernardo, M. T. Hensley, R. Carter, T. P. Williams, H. L. Prichard, M. S. Dey, K. G. Begelman, L. E. Niklason (2011) Readily available tissue-engineered vascular grafts. Sci Transl Med 3: 68ra9.
14.
Daly, R.C., T.A. Orszulak, H.V. Schaff, E. McGovern, R.B. Wallace (1991) Long-term results of aortic valve replacement with nonviable homografts. Circulation 84(5 suppl): III81– III88.
15.
Dodd, P.D. (2010) What tissue bankers should know about the use of allograft blood vessels. Cell Tissue Bank 11: 3–11.
16.
Fischlein, T., A. Schutz, M. Haushofer, R. Frey, A. Uhlig, C. Detter, B. Reichart (1995) Immunologic reaction and viability of cryopreserved homografts. Ann Thorac Surg 60(2 suppl): S122–S125;(discussion)S125–S126.
17.
Gabriel, M., F. Pukacki, L. Dzieciuchowicz, G. Oszkinis, P. Checinski (2004) Cryopreserved arterial allografts in the treatment of prosthetic graft infections. Eur J Vasc Endovasc Surg 27: 590–596.
18.
Hilbert, S.L., R.E. Luna, J. Zhang, Y. Wang, R.A. Hopkins, Z.X. Yu, V.J. Ferrans (1999) Allograft heart valves: the role of apoptosis-mediated cell loss. J Thorac Cardiovasc Surg 117: 454–462.
19.
Jomha, N.M., A.D. Weiss, J. Fraser Forbes, G.K. Law, J.A. Elliott, L.E. McGann (2010) Cryoprotectant agent toxicity in porcine articular chondrocytes. Cryobiology 61: 297–302.
20.
Konig, K., K. Schenke-Layland, I. Riemann, U.A. Stock (2005) Multiphoton autofluorescence imaging of intratissue elastic fibers. Biomaterials 26: 495–500.
21.
Leseche, G., Y. Castier, M.D. Petit, P. Bertrand, M. Kitzis, S. Mussot, M. Besnard, O. Cerceau (2001) Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta. J Vasc Surg 34: 616–622.
22.
Lisy, M., J. Pennecke, K.G.M. Brockbank, O. Fritze, M. Schleicher, K. Schenke-Layland, R. Kaulitz, I. Riemann, C.N. Weber, J. Braun, K.E. Mueller, F. Fend, T. Scheunert, A.D. Gruber, J.M. Albes, A.J. Huber, U.A. Stock (2010) The performance of ice-free cryopreserved heart valve allografts in an orthotopic pulmonary sheep model. Biomaterials 31: 5306–5311.
23.
Muratov, R., D. Britikov, A. Sachkov, V. Akatov, V. Soloviev, I. Fadeeva, L. Bockeria (2010) New approach to reduce allograft tissue immunogenicity. Experimental data. Interact Cardiovasc Thorac Surg 10: 408–412.
24.
Nevelsteen, A., T. Feryn, H. Lacroix, R. Suy, Y. Goffin (1998) Experience with cryopreserved arterial allografts in the treatment of prosthetic graft infections. Cardiovasc Surg 6: 378–383.
25.
O’Brien, J., I. Wilson, T. Orton, F. Pognan (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421–5426.
26.
O’Brien, M.F., E.G. Stafford, M.A. Gardner, P.G. Pohlner, D.C. McGiffin (1987) A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg 94: 812–823.
27.
Pearson, K., N. Dock, S. Brubaker (eds) (2008) Standards for Tissue Banking. American Association of Tissue Banks, ed 12.
28.
Pegg, D. (2010) Cryopreservation, chapter 8; in Galea, G. (ed): Essentials of Tissue Banking, Springer, pp 109–121.
29.
Pelzer, H., A. Schwarz, N. Heimburger (1988) Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 59: 101–106.
30.
Schenke-Layland, K. (2008) Non-invasive multiphoton imaging of extracellular matrix structures. J Biophotonics 1: 451–462.
31.
Schenke-Layland, K., N. Madershahian, I. Riemann, B. Starcher, K.J. Halbhuber, K. Konig, U.A. Stock (2006) Impact of cryopreservation on extracellular matrix structures of heart valve leaflets. Ann Thorac Surg 81: 918–926.
32.
Schenke-Layland, K., I. Riemann, U.A. Stock, K. Konig (2005) Imaging of cardiovascular structures using near-infrared femtosecond multiphoton laser scanning microscopy. J Biomed Opt 10: 024017.
33.
van der Kamp, A.W., J. Nauta (1979) Fibroblast function and the maintenance of the aortic-valve matrix. Cardiovasc Res 13: 167–172.
34.
Vardanian, A.J., A. Chau, W. Quinones-Baldrich, P.E. Lawrence (2009) Arterial allograft allows in-line reconstruction of prosthetic graft infection with low recurrence rate and mortality. Am Surg 75: 1000–1003.
35.
Zahavi, J., V.V. Kakkar (1980) Beta-thromboglobulin – a specific marker of in-vivo platelet release reaction. Thromb Haemost 44: 23–29.
36.
Zhou, J., O. Fritze, M. Schleicher, H.P. Wendel, K. Schenke-Layland, C. Harasztosi, S. Hu, U.A. Stock (2010) Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials 31: 2549–2554.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.